Cerebrospinal fluid and positron-emission tomography biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis

Author:

Lancini Elisa12ORCID,Haag Lena12,Bartl Franziska2,Rühling Maren2,Ashton Nicholas J3456,Zetterberg Henrik7891011ORCID,Düzel Emrah121213ORCID,Hämmerer Dorothea12121314,Betts Matthew J1213

Affiliation:

1. German Center for Neurodegenerative Diseases (DZNE), Otto-von-Guericke University Magdeburg , Magdeburg , Germany

2. Faculty of Medicine, Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University Magdeburg , Magdeburg , Germany

3. Institute of Psychiatry, Department of Old Age Psychiatry, King’s College London , London , UK

4. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg , Gothenburg , Sweden

5. NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation , London , UK

6. Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden

7. Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden

8. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , Mölndal , Sweden

9. Department of Neurodegenerative Disease, UCL Institute of Neurology , London , UK

10. UK Dementia Research Institute at UCL , London , UK

11. Hong Kong Center for Neurodegenerative Diseases , Hong Kong , China

12. Institute of Cognitive Neuroscience, University College London , London , UK

13. Center for Behavioral Brain Sciences, University of Magdeburg , Magdeburg , Germany

14. Department of Psychology, University of Innsbruck , Innsbruck , Austria

Abstract

Abstract The noradrenergic system shows pathological modifications in aging and neurodegenerative diseases and undergoes substantial neuronal loss in Alzheimer’s disease and Parkinson’s disease. While a coherent picture of structural decline in post-mortem and in vivo MRI measures seems to emerge, whether this translates into a consistent decline in available noradrenaline levels is unclear. We conducted a meta-analysis of noradrenergic differences in Alzheimer’s disease dementia and Parkinson’s disease using CSF and PET biomarkers. CSF noradrenaline and 3-methoxy-4-hydroxyphenylglycol levels as well as noradrenaline transporters availability, measured with PET, were summarized from 26 articles using a random-effects model meta-analysis. Compared to controls, individuals with Parkinson’s disease showed significantly decreased levels of CSF noradrenaline and 3-methoxy-4-hydroxyphenylglycol, as well as noradrenaline transporters availability in the hypothalamus. In Alzheimer’s disease dementia, 3-methoxy-4-hydroxyphenylglycol but not noradrenaline levels were increased compared to controls. Both CSF and PET biomarkers of noradrenergic dysfunction reveal significant alterations in Parkinson’s disease and Alzheimer’s disease dementia. However, further studies are required to understand how these biomarkers are associated to the clinical symptoms and pathology.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Oxford University Press (OUP)

Subject

Neurology,Cellular and Molecular Neuroscience,Biological Psychiatry,Psychiatry and Mental health

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3